Apollomics Inc
Veridion Score
Composite trend over time
Why is APLM moving today?
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for APLM.
APLM insider activity
Apollomics Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$57K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | 2026-03-31 | LIN PETER KUAN-HOW | Insider | sell | $15.85 | 3,582 | 12,318 | $57K | SEC Form 4 |
APLM contract awards, year to date.
Public federal awards linked to this ticker.
APLM lobbying filings, year to date.
Registered lobbying filings matched to Apollomics Inc.